Idraparinux Sodium

N/A

Report date: 2022/07/19 20:00:45
NME

Base Information

Drug NameIdraparinux Sodium
Drug Alias Nameidraparinux sodique艾卓肝素钠idraparinuxum natricum艾屈肝素钠艾卓肝素 +[10] 
ClassificationSmall molecules > Carbohydrate
Mechanisms of ActionAntithrombin-III activatorsFactor Xa inactivationThrombin inactivation
TargetsAntithrombin-IIIProthrombinCoagulation factor X
Therapy Area/IndicationsVenous ThrombosisAtrial FibrillationPulmonary Embolism
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[26] 
CombinationsNo
Global Highest StatusPending (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesSanofi
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSanofi
Active IndicationsN/A
Inactive IndicationsVenous ThrombosisAtrial FibrillationPulmonary Embolism

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG